Get the Stockscreener App
104.50
1.37%
-1.50
Rhythm Pharmaceuticals Inc stock is traded at $104.50, with a volume of 266.98K.
It is down -1.37% in the last 24 hours and up +5.11% over the past month.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
See More
Previous Close:
$106.00
Open:
$105.7
24h Volume:
266.98K
Relative Volume:
0.41
Market Cap:
$6.97B
Revenue:
$136.86M
Net Income/Loss:
$-168.69M
P/E Ratio:
-37.19
EPS:
-2.81
Net Cash Flow:
$-113.49M
1W Performance:
-4.16%
1M Performance:
+5.11%
6M Performance:
+57.99%
1Y Performance:
+80.83%
1-Day Range:
$104.07
$106.75
1-Week Range:
$101.00
$109.99
52-Week Range:
$45.91
$116.00
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Name
Rhythm Pharmaceuticals Inc
Sector
Industry
Phone
857-264-4280
Address
222 BERKELEY STREET, BOSTON, MA
Compare RYTM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
104.50 | 7.05B | 136.86M | -168.69M | -113.49M | -2.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
454.96 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
720.49 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
459.64 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
901.71 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.62 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-25-25 | Initiated | Citigroup | Buy |
| Nov-05-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-10-25 | Initiated | Goldman | Buy |
| Jul-07-25 | Initiated | Leerink Partners | Outperform |
| Apr-07-25 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-05-25 | Resumed | Stifel | Buy |
| Jan-02-25 | Initiated | Jefferies | Buy |
| Dec-20-24 | Initiated | Oppenheimer | Outperform |
| Oct-21-24 | Initiated | Guggenheim | Buy |
| Sep-18-24 | Initiated | H.C. Wainwright | Buy |
| Sep-17-24 | Initiated | JMP Securities | Mkt Outperform |
| May-08-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-01-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-18-23 | Resumed | Canaccord Genuity | Buy |
| Aug-08-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-05-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-17-22 | Reiterated | Needham | Buy |
| Mar-02-22 | Resumed | Stifel | Buy |
| Feb-17-22 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-14-21 | Resumed | Goldman | Neutral |
| Aug-04-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Aug-04-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Nov-30-20 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-08-20 | Initiated | Goldman | Sell |
| Jul-12-19 | Upgrade | Stifel | Hold → Buy |
| Jul-08-19 | Initiated | Canaccord Genuity | Buy |
| Mar-13-19 | Initiated | Ladenburg Thalmann | Buy |
| Sep-07-18 | Resumed | Morgan Stanley | Overweight |
| Jun-25-18 | Reiterated | Needham | Buy |
| Jun-15-18 | Reiterated | Needham | Buy |
| Oct-30-17 | Initiated | BofA/Merrill | Buy |
| Oct-30-17 | Initiated | Needham | Buy |
View All
Rhythm Pharmaceuticals Inc Stock (RYTM) Latest News
Will Rhythm Pharmaceuticals Inc. stock gain from government policiesMarket Weekly Review & Low Risk Growth Stock Ideas - Newser
Will Rhythm Pharmaceuticals Inc. (1RV) stock beat growth indexesQuarterly Trade Summary & Free Verified High Yield Trade Plans - Newser
How Rhythm Pharmaceuticals Inc. (1RV) stock responds to bond marketJuly 2025 EndofMonth & Capital Protection Trading Alerts - Newser
Panagora Asset Management Inc. Has $7.55 Million Stock Position in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Rhythm Pharmaceuticals, Inc. $RYTM Shares Acquired by Russell Investments Group Ltd. - MarketBeat
Is Rhythm Pharmaceuticals Inc. stock trading near support levelsMarket Risk Analysis & Reliable Price Action Trade Plans - Newser
Will Rhythm Pharmaceuticals Inc. (1RV) stock profit from automation waveMarket Sentiment Report & Low Risk Profit Maximizing Plans - Newser
Is Rhythm Pharmaceuticals Inc. (1RV) stock at risk of policy regulationQuarterly Trade Summary & Long-Term Capital Growth Strategies - Newser
Is Rhythm Pharmaceuticals Inc. (1RV) stock expanding market penetration2025 Top Decliners & Short-Term Swing Trade Alerts - Newser
JPMorgan Chase & Co. Acquires 639,919 Shares of Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
How Is The Market Feeling About Rhythm Pharmaceuticals Inc? - Benzinga
Rhythm Pharmaceuticals, Inc. $RYTM Shares Sold by Loomis Sayles & Co. L P - MarketBeat
Rhythm Pharmaceuticals, Inc. $RYTM Shares Purchased by Creative Planning - MarketBeat
Avoiding Lag: Real-Time Signals in (RYTM) Movement - news.stocktradersdaily.com
SG Americas Securities LLC Has $391,000 Stock Holdings in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Rhythm Pharmaceuticals initiated with Buy at Citi on Imcivree's potential - MSN
Franklin Resources Inc. Has $34.36 Million Stake in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) Earns Buy Rating from Analysts at Citigroup - MarketBeat
How institutional buying supports Rhythm Pharmaceuticals Inc. stock2025 Buyback Activity & Precise Trade Entry Recommendations - BỘ NỘI VỤ
Citigroup Initiates Coverage of Rhythm Pharmaceuticals (RYTM) with Buy Recommendation - Nasdaq
Rhythm: Maintaining Strong Buy On Acquired Hypothalamic Obesity Drug Progress (RYTM) - Seeking Alpha
Citigroup Initiates Coverage on Rhythm Pharmaceuticals (RYTM) wi - GuruFocus
Citigroup Initiates Rhythm Pharmaceuticals at Buy With $136 Price Target - marketscreener.com
Rhythm Pharmaceuticals Executive Sells Shares - TradingView
[Form 4] RHYTHM PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Rhythm Pharmaceuticals Inc. (RYTM) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Will Rhythm Pharmaceuticals Inc. (1RV) stock enhance shareholder valueOil Prices & Fast Exit/Entry Strategy Plans - newser.com
Can Rhythm Pharmaceuticals Inc. stock rebound after recent weakness2025 Big Picture & High Conviction Buy Zone Picks - newser.com
Officer Cramer Files To Sell 3,350 Of Rhythm Pharmaceuticals Inc [RYTM] - TradingView
Why analysts recommend Rhythm Pharmaceuticals Inc. (1RV) stock2025 Performance Recap & Real-Time Buy Signal Notifications - newser.com
Rhythm Pharmaceuticals Ranked 31st on Deloitte Fast 500 List - citybiz
Why Rhythm Pharmaceuticals Inc. (1RV) stock is favored by hedge fundsSwing Trade & Weekly Top Performers Watchlists - newser.com
Can Rhythm Pharmaceuticals Inc. stock weather global recessionEarnings Growth Report & High Accuracy Swing Trade Signals - newser.com
Is it time to cut losses on Rhythm Pharmaceuticals Inc.Layoff News & Long-Term Growth Stock Strategies - newser.com
Why retail investors favor Rhythm Pharmaceuticals Inc. stockWeekly Trade Recap & Precise Trade Entry Recommendations - newser.com
Rhythm Pharmaceuticals Inc Stock (RYTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Rhythm Pharmaceuticals Inc Stock (RYTM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cramer Pamela J. | Chief Human Resources Officer |
Nov 20 '25 |
Sale |
105.00 |
3,350 |
351,750 |
20,814 |
0.73%
0.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):